#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2 .
1-1	0-1	2	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Obesity Before Liver Transplantation
2-1	4-11	Obesity	abstract[2]	new[2]	coref	4-3[0_2]
2-2	12-18	Before	abstract[2]	new[2]	_	_
2-3	19-24	Liver	abstract[2]|object|event[4]	new[2]|new|new[4]	coref|coref	20-7|20-7
2-4	25-40	Transplantation	abstract[2]|event[4]	new[2]|new[4]	_	_

#Text=2.1 .
3-1	41-44	2.1	abstract	new	_	_
3-2	45-46	.	_	_	_	_

#Text=How Should Obesity be Defined in Patients with Cirrhosis Considered for LT ?
4-1	47-50	How	_	_	_	_
4-2	51-57	Should	_	_	_	_
4-3	58-65	Obesity	abstract	giv	coref	5-7
4-4	66-68	be	_	_	_	_
4-5	69-76	Defined	_	_	_	_
4-6	77-79	in	_	_	_	_
4-7	80-88	Patients	person[7]	new[7]	coref	5-26[0_7]
4-8	89-93	with	person[7]	new[7]	_	_
4-9	94-103	Cirrhosis	person[7]|abstract	new[7]|new	coref	14-11[50_0]
4-10	104-114	Considered	_	_	_	_
4-11	115-118	for	_	_	_	_
4-12	119-121	LT	abstract	new	coref	14-29
4-13	122-123	?	_	_	_	_

#Text=The first obstacle is to define obesity in this population . Elamparast et al. recently summarized the most commonly used definitions in this group of patients :
5-1	124-127	The	abstract[10]	new[10]	_	_
5-2	128-133	first	abstract[10]	new[10]	_	_
5-3	134-142	obstacle	abstract[10]	new[10]	_	_
5-4	143-145	is	_	_	_	_
5-5	146-148	to	_	_	_	_
5-6	149-155	define	_	_	_	_
5-7	156-163	obesity	abstract	giv	coref	15-17[59_0]
5-8	164-166	in	_	_	_	_
5-9	167-171	this	person[12]	new[12]	coref	7-6[19_12]
5-10	172-182	population	person[12]	new[12]	_	_
5-11	183-184	.	_	_	_	_
5-12	185-195	Elamparast	_	_	_	_
5-13	196-198	et	_	_	_	_
5-14	199-202	al.	_	_	_	_
5-15	203-211	recently	_	_	_	_
5-16	212-222	summarized	_	_	_	_
5-17	223-226	the	abstract[13]	new[13]	_	_
5-18	227-231	most	abstract[13]	new[13]	_	_
5-19	232-240	commonly	abstract[13]	new[13]	_	_
5-20	241-245	used	abstract[13]	new[13]	_	_
5-21	246-257	definitions	abstract[13]	new[13]	_	_
5-22	258-260	in	abstract[13]	new[13]	_	_
5-23	261-265	this	abstract[13]|person[14]	new[13]|new[14]	_	_
5-24	266-271	group	abstract[13]|person[14]	new[13]|new[14]	_	_
5-25	272-274	of	abstract[13]|person[14]	new[13]|new[14]	_	_
5-26	275-283	patients	abstract[13]|person[14]|person	new[13]|new[14]|giv	coref	14-9[49_0]
5-27	284-285	:	_	_	_	_

#Text=-
6-1	286-287	-	_	_	_	_

#Text=BMI ≥ 30 kg/m2 ( Asian population : ≥25 kg/m2 ) ;
7-1	288-291	BMI	organization|quantity[17]	new|new[17]	appos|coref|appos|coref	7-3[18_17]|14-4|7-3[18_17]|14-4
7-2	292-293	≥	quantity[17]	new[17]	_	_
7-3	294-296	30	quantity[18]	giv[18]	appos	7-9[20_18]
7-4	297-302	kg/m2	quantity[18]	giv[18]	_	_
7-5	303-304	(	_	_	_	_
7-6	305-310	Asian	person[19]	giv[19]	_	_
7-7	311-321	population	person[19]	giv[19]	_	_
7-8	322-323	:	_	_	_	_
7-9	324-327	≥25	quantity[20]	giv[20]	coref	24-11[0_20]
7-10	328-333	kg/m2	quantity[20]	giv[20]	_	_
7-11	334-335	)	_	_	_	_
7-12	336-337	;	_	_	_	_

#Text=-
8-1	338-339	-	_	_	_	_

#Text=Percentage of fat mass ≥28 % in men and ≥40 % in women ;
9-1	340-350	Percentage	quantity[21]	new[21]	_	_
9-2	351-353	of	quantity[21]	new[21]	_	_
9-3	354-357	fat	quantity[21]|substance|quantity[24]	new[21]|new|new[24]	coref|coref	13-2|13-2
9-4	358-362	mass	quantity[21]|quantity|quantity[24]	new[21]|new|new[24]	_	_
9-5	363-366	≥28	quantity[21]|quantity[24]	new[21]|new[24]	_	_
9-6	367-368	%	quantity[21]|quantity[24]	new[21]|new[24]	_	_
9-7	369-371	in	quantity[21]|quantity[24]	new[21]|new[24]	_	_
9-8	372-375	men	quantity[21]|quantity[24]|person	new[21]|new[24]|new	coref	11-6
9-9	376-379	and	quantity[21]|quantity[24]	new[21]|new[24]	_	_
9-10	380-383	≥40	quantity[21]|quantity[24]|quantity[26]	new[21]|new[24]|new[26]	_	_
9-11	384-385	%	quantity[21]|quantity[24]|quantity[26]	new[21]|new[24]|new[26]	_	_
9-12	386-388	in	quantity[21]|quantity[24]|quantity[26]	new[21]|new[24]|new[26]	_	_
9-13	389-394	women	quantity[21]|quantity[24]|quantity[26]|person	new[21]|new[24]|new[26]|new	coref	11-11
9-14	395-396	;	_	_	_	_

#Text=-
10-1	397-398	-	_	_	_	_

#Text=Waist circumference ˃102 cm in men and ˃88 cm in women ( Asian population : A waist circumference ˃90 cm in men and ˃80 cm in women ) ;
11-1	399-404	Waist	object|place[29]	new|new[29]	coref|coref|coref|coref	11-17|11-16[36_29]|11-17|11-16[36_29]
11-2	405-418	circumference	place[29]	new[29]	_	_
11-3	419-423	˃102	quantity[30]	new[30]	_	_
11-4	424-426	cm	quantity[30]	new[30]	_	_
11-5	427-429	in	quantity[30]	new[30]	_	_
11-6	430-433	men	quantity[30]|person	new[30]|giv	coref	11-22
11-7	434-437	and	_	_	_	_
11-8	438-441	˃88	quantity[32]	new[32]	coref	11-19[37_32]
11-9	442-444	cm	quantity[32]	new[32]	_	_
11-10	445-447	in	quantity[32]	new[32]	_	_
11-11	448-453	women	quantity[32]|person	new[32]|giv	appos	11-13[34_0]
11-12	454-455	(	_	_	_	_
11-13	456-461	Asian	person[34]	giv[34]	coref	11-27[0_34]
11-14	462-472	population	person[34]	giv[34]	_	_
11-15	473-474	:	_	_	_	_
11-16	475-476	A	place[36]	giv[36]	coref	22-6[118_36]
11-17	477-482	waist	object|place[36]	giv|giv[36]	coref	22-6
11-18	483-496	circumference	place[36]	giv[36]	_	_
11-19	497-500	˃90	place[36]|quantity[37]	giv[36]|giv[37]	coref	11-24[39_37]
11-20	501-503	cm	place[36]|quantity[37]	giv[36]|giv[37]	_	_
11-21	504-506	in	place[36]|quantity[37]	giv[36]|giv[37]	_	_
11-22	507-510	men	place[36]|quantity[37]|person	giv[36]|giv[37]|giv	_	_
11-23	511-514	and	_	_	_	_
11-24	515-518	˃80	quantity[39]	giv[39]	_	_
11-25	519-521	cm	quantity[39]	giv[39]	_	_
11-26	522-524	in	quantity[39]	giv[39]	_	_
11-27	525-530	women	quantity[39]|person	giv[39]|giv	_	_
11-28	531-532	)	_	_	_	_
11-29	533-534	;	_	_	_	_

#Text=-
12-1	535-536	-	_	_	_	_

#Text=Visceral fat area ≥100 cm2 on abdominal computed tomography .
13-1	537-545	Visceral	abstract[42]	new[42]	coref	25-14[159_42]
13-2	546-549	fat	substance|abstract[42]	giv|new[42]	coref	19-1[93_0]
13-3	550-554	area	abstract[42]	new[42]	_	_
13-4	555-559	≥100	quantity[43]	new[43]	_	_
13-5	560-563	cm2	quantity[43]	new[43]	_	_
13-6	564-566	on	quantity[43]	new[43]	_	_
13-7	567-576	abdominal	quantity[43]|person	new[43]|new	_	_
13-8	577-585	computed	_	_	_	_
13-9	586-596	tomography	object	new	_	_
13-10	597-598	.	_	_	_	_

#Text=The use of BMI has several limitations in patients with decompensated cirrhosis , as reflected by the fact that sarcopenia outperforms BMI as a predictor of outcomes after LT .
14-1	599-602	The	abstract[46]	new[46]	coref	24-30[153_46]
14-2	603-606	use	abstract[46]	new[46]	_	_
14-3	607-609	of	abstract[46]	new[46]	_	_
14-4	610-613	BMI	abstract[46]|organization	new[46]|giv	coref	14-22
14-5	614-617	has	_	_	_	_
14-6	618-625	several	abstract[48]	new[48]	coref	23-6[123_48]
14-7	626-637	limitations	abstract[48]	new[48]	_	_
14-8	638-640	in	abstract[48]	new[48]	_	_
14-9	641-649	patients	abstract[48]|person[49]	new[48]|giv[49]	coref	15-46[0_49]
14-10	650-654	with	abstract[48]|person[49]	new[48]|giv[49]	_	_
14-11	655-668	decompensated	abstract[48]|person[49]|abstract[50]	new[48]|giv[49]|giv[50]	coref	18-33[92_50]
14-12	669-678	cirrhosis	abstract[48]|person[49]|abstract[50]	new[48]|giv[49]|giv[50]	_	_
14-13	679-680	,	_	_	_	_
14-14	681-683	as	_	_	_	_
14-15	684-693	reflected	_	_	_	_
14-16	694-696	by	_	_	_	_
14-17	697-700	the	abstract[51]	new[51]	coref	21-3[108_51]
14-18	701-705	fact	abstract[51]	new[51]	_	_
14-19	706-710	that	abstract[51]	new[51]	_	_
14-20	711-721	sarcopenia	abstract[51]|abstract	new[51]|new	coref	18-12
14-21	722-733	outperforms	abstract[51]	new[51]	_	_
14-22	734-737	BMI	abstract[51]|organization	new[51]|giv	coref	15-5[56_0]
14-23	738-740	as	_	_	_	_
14-24	741-742	a	_	_	_	_
14-25	743-752	predictor	_	_	_	_
14-26	753-755	of	_	_	_	_
14-27	756-764	outcomes	abstract	new	coref	23-72[142_0]
14-28	765-770	after	_	_	_	_
14-29	771-773	LT	event	giv	coref	15-40
14-30	774-775	.	_	_	_	_

#Text=First of all , a high BMI may be due to fluid overload/ascites , and not obesity per se , as exemplified in a study in which adjusting BMI for the liters of ascites drained at the time of LT resulted in moving one-fifth of patients from one BMI category to a lower one .
15-1	776-781	First	_	_	_	_
15-2	782-784	of	_	_	_	_
15-3	785-788	all	_	_	_	_
15-4	789-790	,	_	_	_	_
15-5	791-792	a	organization[56]	giv[56]	coref	15-29[0_56]
15-6	793-797	high	organization[56]	giv[56]	_	_
15-7	798-801	BMI	organization[56]	giv[56]	_	_
15-8	802-805	may	_	_	_	_
15-9	806-808	be	_	_	_	_
15-10	809-812	due	_	_	_	_
15-11	813-815	to	_	_	_	_
15-12	816-821	fluid	substance|abstract[58]	new|new[58]	coref|coref	23-35|23-35
15-13	822-838	overload/ascites	abstract[58]	new[58]	_	_
15-14	839-840	,	_	_	_	_
15-15	841-844	and	_	_	_	_
15-16	845-848	not	_	_	_	_
15-17	849-856	obesity	abstract[59]	giv[59]	coref	22-15[120_59]
15-18	857-860	per	abstract[59]	giv[59]	_	_
15-19	861-863	se	abstract[59]|abstract	giv[59]|new	_	_
15-20	864-865	,	_	_	_	_
15-21	866-868	as	_	_	_	_
15-22	869-880	exemplified	_	_	_	_
15-23	881-883	in	_	_	_	_
15-24	884-885	a	event[61]	new[61]	_	_
15-25	886-891	study	event[61]	new[61]	_	_
15-26	892-894	in	_	_	_	_
15-27	895-900	which	_	_	_	_
15-28	901-910	adjusting	_	_	_	_
15-29	911-914	BMI	organization	giv	coref	15-49
15-30	915-918	for	_	_	_	_
15-31	919-922	the	quantity[63]	new[63]	_	_
15-32	923-929	liters	quantity[63]	new[63]	_	_
15-33	930-932	of	quantity[63]	new[63]	_	_
15-34	933-940	ascites	quantity[63]|abstract	new[63]|new	coref	23-53
15-35	941-948	drained	_	_	_	_
15-36	949-951	at	_	_	_	_
15-37	952-955	the	_	_	_	_
15-38	956-960	time	_	_	_	_
15-39	961-963	of	_	_	_	_
15-40	964-966	LT	event	giv	coref	23-68
15-41	967-975	resulted	_	_	_	_
15-42	976-978	in	_	_	_	_
15-43	979-985	moving	_	_	_	_
15-44	986-995	one-fifth	abstract[66]	new[66]	_	_
15-45	996-998	of	abstract[66]	new[66]	_	_
15-46	999-1007	patients	abstract[66]|person	new[66]|giv	coref	18-28[91_0]
15-47	1008-1012	from	_	_	_	_
15-48	1013-1016	one	abstract[69]	new[69]	_	_
15-49	1017-1020	BMI	organization|abstract[69]	giv|new[69]	coref	16-3
15-50	1021-1029	category	abstract[69]	new[69]	_	_
15-51	1030-1032	to	abstract[69]	new[69]	_	_
15-52	1033-1034	a	abstract[69]|abstract[70]	new[69]|new[70]	coref	18-14[88_70]
15-53	1035-1040	lower	abstract[69]|abstract[70]	new[69]|new[70]	_	_
15-54	1041-1044	one	abstract[69]|abstract[70]	new[69]|new[70]	_	_
15-55	1045-1046	.	_	_	_	_

#Text=Also , BMI gives no information about body composition :
16-1	1047-1051	Also	_	_	_	_
16-2	1052-1053	,	_	_	_	_
16-3	1054-1057	BMI	organization	giv	coref	18-21
16-4	1058-1063	gives	_	_	_	_
16-5	1064-1066	no	abstract[72]	new[72]	_	_
16-6	1067-1078	information	abstract[72]	new[72]	_	_
16-7	1079-1084	about	abstract[72]	new[72]	_	_
16-8	1085-1089	body	abstract[72]|object|abstract[74]	new[72]|new|new[74]	ana|coref|ana|coref	17-1[0_74]|18-4|17-1[0_74]|18-4
16-9	1090-1101	composition	abstract[72]|abstract[74]	new[72]|new[74]	_	_
16-10	1102-1103	:	_	_	_	_

#Text=It cannot tell the difference between muscle , subcutaneous , or visceral adipose tissue , which have different implications .
17-1	1104-1106	It	abstract	giv	coref	18-4[83_0]
17-2	1107-1113	cannot	_	_	_	_
17-3	1114-1118	tell	_	_	_	_
17-4	1119-1122	the	abstract[76]	new[76]	_	_
17-5	1123-1133	difference	abstract[76]	new[76]	_	_
17-6	1134-1141	between	abstract[76]	new[76]	_	_
17-7	1142-1148	muscle	abstract[76]|object	new[76]|new	_	_
17-8	1149-1150	,	abstract[76]	new[76]	_	_
17-9	1151-1163	subcutaneous	abstract[76]	new[76]	_	_
17-10	1164-1165	,	abstract[76]	new[76]	_	_
17-11	1166-1168	or	abstract[76]	new[76]	_	_
17-12	1169-1177	visceral	abstract[76]|object[79]	new[76]|new[79]	_	_
17-13	1178-1185	adipose	abstract[76]|abstract|object[79]	new[76]|new|new[79]	coref	18-16
17-14	1186-1192	tissue	abstract[76]|object[79]	new[76]|new[79]	_	_
17-15	1193-1194	,	_	_	_	_
17-16	1195-1200	which	_	_	_	_
17-17	1201-1205	have	_	_	_	_
17-18	1206-1215	different	abstract[80]	new[80]	_	_
17-19	1216-1228	implications	abstract[80]	new[80]	_	_
17-20	1229-1230	.	_	_	_	_

#Text=Studies looking at body composition on cross-sectional imaging have found that sarcopenia and low subcutaneous adipose tissue , but not BMI , are associated with mortality in male and female patients with cirrhosis , respectively .
18-1	1231-1238	Studies	abstract	new	_	_
18-2	1239-1246	looking	_	_	_	_
18-3	1247-1249	at	_	_	_	_
18-4	1250-1254	body	object|abstract[83]	giv|giv[83]	coref|coref	25-19|25-19
18-5	1255-1266	composition	abstract[83]	giv[83]	_	_
18-6	1267-1269	on	abstract[83]	giv[83]	_	_
18-7	1270-1285	cross-sectional	abstract[83]|object[84]	giv[83]|new[84]	_	_
18-8	1286-1293	imaging	abstract[83]|object[84]	giv[83]|new[84]	_	_
18-9	1294-1298	have	_	_	_	_
18-10	1299-1304	found	_	_	_	_
18-11	1305-1309	that	_	_	_	_
18-12	1310-1320	sarcopenia	abstract	giv	coref	19-7
18-13	1321-1324	and	_	_	_	_
18-14	1325-1328	low	object[88]	giv[88]	coref	20-25[105_88]
18-15	1329-1341	subcutaneous	abstract|object[88]	new|giv[88]	coref	25-49
18-16	1342-1349	adipose	abstract|object[88]	giv|giv[88]	coref	25-50
18-17	1350-1356	tissue	object[88]	giv[88]	_	_
18-18	1357-1358	,	_	_	_	_
18-19	1359-1362	but	_	_	_	_
18-20	1363-1366	not	_	_	_	_
18-21	1367-1370	BMI	organization	giv	coref	21-17[112_0]
18-22	1371-1372	,	_	_	_	_
18-23	1373-1376	are	_	_	_	_
18-24	1377-1387	associated	_	_	_	_
18-25	1388-1392	with	_	_	_	_
18-26	1393-1402	mortality	abstract[90]	new[90]	coref	19-20[96_90]
18-27	1403-1405	in	abstract[90]	new[90]	_	_
18-28	1406-1410	male	abstract[90]|person[91]	new[90]|giv[91]	coref	20-12[101_91]
18-29	1411-1414	and	abstract[90]|person[91]	new[90]|giv[91]	_	_
18-30	1415-1421	female	abstract[90]|person[91]	new[90]|giv[91]	_	_
18-31	1422-1430	patients	abstract[90]|person[91]	new[90]|giv[91]	_	_
18-32	1431-1435	with	abstract[90]|person[91]	new[90]|giv[91]	_	_
18-33	1436-1445	cirrhosis	abstract[90]|person[91]|abstract[92]	new[90]|giv[91]|giv[92]	coref	23-24[0_92]
18-34	1446-1447	,	abstract[90]|person[91]|abstract[92]	new[90]|giv[91]|giv[92]	_	_
18-35	1448-1460	respectively	abstract[90]|person[91]|abstract[92]	new[90]|giv[91]|giv[92]	_	_
18-36	1461-1462	.	_	_	_	_

#Text=Excessive visceral fat when associated with sarcopenia , a term known as sarcopenic obesity , is also associated with increased mortality .
19-1	1463-1472	Excessive	substance[93]	giv[93]	coref	25-16[0_93]
19-2	1473-1481	visceral	substance[93]	giv[93]	_	_
19-3	1482-1485	fat	substance[93]	giv[93]	_	_
19-4	1486-1490	when	_	_	_	_
19-5	1491-1501	associated	_	_	_	_
19-6	1502-1506	with	_	_	_	_
19-7	1507-1517	sarcopenia	abstract	giv	appos	19-9[95_0]
19-8	1518-1519	,	_	_	_	_
19-9	1520-1521	a	abstract[95]	giv[95]	coref	20-14[0_95]
19-10	1522-1526	term	abstract[95]	giv[95]	_	_
19-11	1527-1532	known	_	_	_	_
19-12	1533-1535	as	_	_	_	_
19-13	1536-1546	sarcopenic	_	_	_	_
19-14	1547-1554	obesity	_	_	_	_
19-15	1555-1556	,	_	_	_	_
19-16	1557-1559	is	_	_	_	_
19-17	1560-1564	also	_	_	_	_
19-18	1565-1575	associated	_	_	_	_
19-19	1576-1580	with	_	_	_	_
19-20	1581-1590	increased	abstract[96]	giv[96]	coref	20-37[0_96]
19-21	1591-1600	mortality	abstract[96]	giv[96]	_	_
19-22	1601-1602	.	_	_	_	_

#Text=In the case of living donor liver transplant ( LDLT ) patients , sarcopenia , myosteatosis , and the visceral-to-subcutaneous-adipose-tissue ratio , but not visceral or subcutaneous tissue on their own , have been associated with mortality .
20-1	1603-1605	In	_	_	_	_
20-2	1606-1609	the	abstract[97]	new[97]	_	_
20-3	1610-1614	case	abstract[97]	new[97]	_	_
20-4	1615-1617	of	_	_	_	_
20-5	1618-1624	living	_	_	_	_
20-6	1625-1630	donor	person[99]	new[99]	_	_
20-7	1631-1636	liver	object|person[99]	giv|new[99]	coref	23-17
20-8	1637-1647	transplant	person[99]	new[99]	_	_
20-9	1648-1649	(	_	_	_	_
20-10	1650-1654	LDLT	abstract	new	_	_
20-11	1655-1656	)	_	_	_	_
20-12	1657-1665	patients	person[101]	giv[101]	coref	22-17[121_101]
20-13	1666-1667	,	person[101]	giv[101]	_	_
20-14	1668-1678	sarcopenia	person[101]|abstract	giv[101]|giv	coref	25-43
20-15	1679-1680	,	person[101]	giv[101]	_	_
20-16	1681-1693	myosteatosis	person[101]|abstract	giv[101]|new	_	_
20-17	1694-1695	,	person[101]	giv[101]	_	_
20-18	1696-1699	and	person[101]	giv[101]	_	_
20-19	1700-1703	the	person[101]|quantity[104]	giv[101]|new[104]	_	_
20-20	1704-1743	visceral-to-subcutaneous-adipose-tissue	person[101]|quantity[104]	giv[101]|new[104]	_	_
20-21	1744-1749	ratio	person[101]|quantity[104]	giv[101]|new[104]	_	_
20-22	1750-1751	,	person[101]	giv[101]	_	_
20-23	1752-1755	but	person[101]	giv[101]	_	_
20-24	1756-1759	not	person[101]	giv[101]	_	_
20-25	1760-1768	visceral	person[101]|object[105]	giv[101]|giv[105]	coref	25-48[172_105]
20-26	1769-1771	or	person[101]|object[105]	giv[101]|giv[105]	_	_
20-27	1772-1784	subcutaneous	person[101]|object[105]	giv[101]|giv[105]	_	_
20-28	1785-1791	tissue	person[101]|object[105]	giv[101]|giv[105]	_	_
20-29	1792-1794	on	person[101]|object[105]	giv[101]|giv[105]	_	_
20-30	1795-1800	their	person[101]|object[105]	giv[101]|giv[105]	_	_
20-31	1801-1804	own	person[101]|object[105]	giv[101]|giv[105]	_	_
20-32	1805-1806	,	_	_	_	_
20-33	1807-1811	have	_	_	_	_
20-34	1812-1816	been	_	_	_	_
20-35	1817-1827	associated	_	_	_	_
20-36	1828-1832	with	_	_	_	_
20-37	1833-1842	mortality	abstract	giv	ana	21-1
20-38	1843-1844	.	_	_	_	_

#Text=This reinforces the fact that more than the size of a patient , which is what the BMI stands for , it is the composition that matters .
21-1	1845-1849	This	abstract	giv	ana	21-5
21-2	1850-1860	reinforces	_	_	_	_
21-3	1861-1864	the	abstract[108]	giv[108]	_	_
21-4	1865-1869	fact	abstract[108]	giv[108]	_	_
21-5	1870-1874	that	abstract	giv	ana	21-22
21-6	1875-1879	more	quantity[110]	new[110]	_	_
21-7	1880-1884	than	quantity[110]	new[110]	_	_
21-8	1885-1888	the	quantity[110]	new[110]	_	_
21-9	1889-1893	size	quantity[110]	new[110]	_	_
21-10	1894-1896	of	quantity[110]	new[110]	_	_
21-11	1897-1898	a	quantity[110]|person[111]	new[110]|new[111]	coref	33-17[237_111]
21-12	1899-1906	patient	quantity[110]|person[111]	new[110]|new[111]	_	_
21-13	1907-1908	,	_	_	_	_
21-14	1909-1914	which	_	_	_	_
21-15	1915-1917	is	_	_	_	_
21-16	1918-1922	what	_	_	_	_
21-17	1923-1926	the	organization[112]	giv[112]	coref	23-28[131_112]
21-18	1927-1930	BMI	organization[112]	giv[112]	_	_
21-19	1931-1937	stands	_	_	_	_
21-20	1938-1941	for	_	_	_	_
21-21	1942-1943	,	_	_	_	_
21-22	1944-1946	it	abstract	giv	coref	21-24[114_0]
21-23	1947-1949	is	_	_	_	_
21-24	1950-1953	the	abstract[114]	giv[114]	coref	25-20[0_114]
21-25	1954-1965	composition	abstract[114]	giv[114]	_	_
21-26	1966-1970	that	_	_	_	_
21-27	1971-1978	matters	event	new	_	_
21-28	1979-1980	.	_	_	_	_

#Text=For the same reasons , waist circumference is not the best method to assess obesity in these patients .
22-1	1981-1984	For	_	_	_	_
22-2	1985-1988	the	abstract[116]	new[116]	ana	23-4[122_116]
22-3	1989-1993	same	abstract[116]	new[116]	_	_
22-4	1994-2001	reasons	abstract[116]	new[116]	_	_
22-5	2002-2003	,	_	_	_	_
22-6	2004-2009	waist	object|place[118]	giv|giv[118]	_	_
22-7	2010-2023	circumference	place[118]	giv[118]	_	_
22-8	2024-2026	is	_	_	_	_
22-9	2027-2030	not	_	_	_	_
22-10	2031-2034	the	abstract[119]	new[119]	_	_
22-11	2035-2039	best	abstract[119]	new[119]	_	_
22-12	2040-2046	method	abstract[119]	new[119]	_	_
22-13	2047-2049	to	_	_	_	_
22-14	2050-2056	assess	_	_	_	_
22-15	2057-2064	obesity	abstract[120]	giv[120]	coref	25-9[0_120]
22-16	2065-2067	in	abstract[120]	giv[120]	_	_
22-17	2068-2073	these	abstract[120]|person[121]	giv[120]|giv[121]	coref	23-22[129_121]
22-18	2074-2082	patients	abstract[120]|person[121]	giv[120]|giv[121]	_	_
22-19	2083-2084	.	_	_	_	_

#Text=Trying to circumvent some of these limitations , the European Association for the Study of the Liver guidelines for nutrition in patients with cirrhosis recommend to adjust the BMI for the confounding effect of fluid retention ( i. e. , dry-BMI ) , though there is no perfect correlation between BMI and ascites , and in fact , BMI corrected for ascites drained at the time of LT failed to predict relevant outcomes after LT .
23-1	2085-2091	Trying	_	_	_	_
23-2	2092-2094	to	_	_	_	_
23-3	2095-2105	circumvent	_	_	_	_
23-4	2106-2110	some	abstract[122]	giv[122]	_	_
23-5	2111-2113	of	abstract[122]	giv[122]	_	_
23-6	2114-2119	these	abstract[122]|abstract[123]	giv[122]|giv[123]	_	_
23-7	2120-2131	limitations	abstract[122]|abstract[123]	giv[122]|giv[123]	_	_
23-8	2132-2133	,	_	_	_	_
23-9	2134-2137	the	organization[124]	new[124]	coref	28-18[182_124]
23-10	2138-2146	European	organization[124]	new[124]	_	_
23-11	2147-2158	Association	organization[124]	new[124]	_	_
23-12	2159-2162	for	organization[124]	new[124]	_	_
23-13	2163-2166	the	organization[124]|abstract[125]	new[124]|new[125]	_	_
23-14	2167-2172	Study	organization[124]|abstract[125]	new[124]|new[125]	_	_
23-15	2173-2175	of	organization[124]|abstract[125]	new[124]|new[125]	_	_
23-16	2176-2179	the	organization[124]|abstract[125]|abstract[127]	new[124]|new[125]|new[127]	_	_
23-17	2180-2185	Liver	organization[124]|abstract[125]|object|abstract[127]	new[124]|new[125]|giv|new[127]	coref	28-25[184_0]
23-18	2186-2196	guidelines	organization[124]|abstract[125]|abstract[127]	new[124]|new[125]|new[127]	_	_
23-19	2197-2200	for	organization[124]|abstract[125]|abstract[127]	new[124]|new[125]|new[127]	_	_
23-20	2201-2210	nutrition	organization[124]|abstract[125]|abstract[127]|abstract	new[124]|new[125]|new[127]|new	_	_
23-21	2211-2213	in	organization[124]|abstract[125]|abstract[127]	new[124]|new[125]|new[127]	_	_
23-22	2214-2222	patients	organization[124]|abstract[125]|abstract[127]|person[129]	new[124]|new[125]|new[127]|giv[129]	coref	27-2[174_129]
23-23	2223-2227	with	organization[124]|abstract[125]|abstract[127]|person[129]	new[124]|new[125]|new[127]|giv[129]	_	_
23-24	2228-2237	cirrhosis	organization[124]|abstract[125]|abstract[127]|person[129]|abstract	new[124]|new[125]|new[127]|giv[129]|giv	_	_
23-25	2238-2247	recommend	_	_	_	_
23-26	2248-2250	to	_	_	_	_
23-27	2251-2257	adjust	_	_	_	_
23-28	2258-2261	the	organization[131]	giv[131]	coref	23-51[0_131]
23-29	2262-2265	BMI	organization[131]	giv[131]	_	_
23-30	2266-2269	for	organization[131]	giv[131]	_	_
23-31	2270-2273	the	organization[131]|abstract[132]	giv[131]|new[132]	_	_
23-32	2274-2285	confounding	organization[131]|abstract[132]	giv[131]|new[132]	_	_
23-33	2286-2292	effect	organization[131]|abstract[132]	giv[131]|new[132]	_	_
23-34	2293-2295	of	organization[131]|abstract[132]	giv[131]|new[132]	_	_
23-35	2296-2301	fluid	organization[131]|abstract[132]|substance|abstract[134]	giv[131]|new[132]|giv|new[134]	_	_
23-36	2302-2311	retention	organization[131]|abstract[132]|abstract[134]	giv[131]|new[132]|new[134]	_	_
23-37	2312-2313	(	_	_	_	_
23-38	2314-2316	i.	_	_	_	_
23-39	2317-2319	e.	_	_	_	_
23-40	2320-2321	,	_	_	_	_
23-41	2322-2329	dry-BMI	abstract	new	_	_
23-42	2330-2331	)	_	_	_	_
23-43	2332-2333	,	_	_	_	_
23-44	2334-2340	though	_	_	_	_
23-45	2341-2346	there	_	_	_	_
23-46	2347-2349	is	_	_	_	_
23-47	2350-2352	no	abstract[136]	new[136]	_	_
23-48	2353-2360	perfect	abstract[136]	new[136]	_	_
23-49	2361-2372	correlation	abstract[136]	new[136]	_	_
23-50	2373-2380	between	abstract[136]	new[136]	_	_
23-51	2381-2384	BMI	abstract[136]|abstract	new[136]|giv	coref	23-59
23-52	2385-2388	and	abstract[136]	new[136]	_	_
23-53	2389-2396	ascites	abstract[136]|abstract	new[136]|giv	coref	23-62
23-54	2397-2398	,	abstract[136]	new[136]	_	_
23-55	2399-2402	and	abstract[136]	new[136]	_	_
23-56	2403-2405	in	abstract[136]	new[136]	_	_
23-57	2406-2410	fact	abstract[136]	new[136]	_	_
23-58	2411-2412	,	abstract[136]	new[136]	_	_
23-59	2413-2416	BMI	abstract[136]|abstract	new[136]|giv	coref	24-3[144_0]
23-60	2417-2426	corrected	_	_	_	_
23-61	2427-2430	for	_	_	_	_
23-62	2431-2438	ascites	abstract	giv	_	_
23-63	2439-2446	drained	_	_	_	_
23-64	2447-2449	at	_	_	_	_
23-65	2450-2453	the	_	_	_	_
23-66	2454-2458	time	_	_	_	_
23-67	2459-2461	of	_	_	_	_
23-68	2462-2464	LT	event	giv	coref	23-75
23-69	2465-2471	failed	_	_	_	_
23-70	2472-2474	to	_	_	_	_
23-71	2475-2482	predict	_	_	_	_
23-72	2483-2491	relevant	abstract[142]	giv[142]	coref	24-34[154_142]
23-73	2492-2500	outcomes	abstract[142]	giv[142]	_	_
23-74	2501-2506	after	_	_	_	_
23-75	2507-2509	LT	event	giv	coref	25-35
23-76	2510-2511	.	_	_	_	_

#Text=Likewise , a modified BMI calculated by multiplying BMI ( kg/m2 ) by serum albumin ( g/L ) with the intention of compensating for volume overload was found of no use to predict clinical outcomes .
24-1	2512-2520	Likewise	_	_	_	_
24-2	2521-2522	,	_	_	_	_
24-3	2523-2524	a	organization[144]	giv[144]	coref	24-9[0_144]
24-4	2525-2533	modified	organization[144]	giv[144]	_	_
24-5	2534-2537	BMI	organization[144]	giv[144]	_	_
24-6	2538-2548	calculated	_	_	_	_
24-7	2549-2551	by	_	_	_	_
24-8	2552-2563	multiplying	_	_	_	_
24-9	2564-2567	BMI	abstract	giv	coref	31-10
24-10	2568-2569	(	_	_	_	_
24-11	2570-2575	kg/m2	quantity	giv	_	_
24-12	2576-2577	)	_	_	_	_
24-13	2578-2580	by	_	_	_	_
24-14	2581-2586	serum	abstract|substance[148]	new|new[148]	_	_
24-15	2587-2594	albumin	substance[148]	new[148]	_	_
24-16	2595-2596	(	_	_	_	_
24-17	2597-2600	g/L	quantity	new	_	_
24-18	2601-2602	)	_	_	_	_
24-19	2603-2607	with	_	_	_	_
24-20	2608-2611	the	abstract[150]	new[150]	_	_
24-21	2612-2621	intention	abstract[150]	new[150]	_	_
24-22	2622-2624	of	_	_	_	_
24-23	2625-2637	compensating	_	_	_	_
24-24	2638-2641	for	_	_	_	_
24-25	2642-2648	volume	abstract|abstract[152]	new|new[152]	_	_
24-26	2649-2657	overload	abstract[152]	new[152]	_	_
24-27	2658-2661	was	_	_	_	_
24-28	2662-2667	found	_	_	_	_
24-29	2668-2670	of	_	_	_	_
24-30	2671-2673	no	abstract[153]	giv[153]	_	_
24-31	2674-2677	use	abstract[153]	giv[153]	_	_
24-32	2678-2680	to	_	_	_	_
24-33	2681-2688	predict	_	_	_	_
24-34	2689-2697	clinical	abstract[154]	giv[154]	coref	29-10[0_154]
24-35	2698-2706	outcomes	abstract[154]	giv[154]	_	_
24-36	2707-2708	.	_	_	_	_

#Text=In conclusion , when available , we suggest obesity be defined according to the visceral fat area on body composition analysis , especially in the research setting , because the impact of obesity on LT may be modified by the coexistence of sarcopenia , myosteatosis , and/or low subcutaneous adipose tissue .
25-1	2709-2711	In	_	_	_	_
25-2	2712-2722	conclusion	abstract	new	_	_
25-3	2723-2724	,	_	_	_	_
25-4	2725-2729	when	_	_	_	_
25-5	2730-2739	available	_	_	_	_
25-6	2740-2741	,	_	_	_	_
25-7	2742-2744	we	person	acc	_	_
25-8	2745-2752	suggest	_	_	_	_
25-9	2753-2760	obesity	abstract	giv	coref	25-33
25-10	2761-2763	be	_	_	_	_
25-11	2764-2771	defined	_	_	_	_
25-12	2772-2781	according	_	_	_	_
25-13	2782-2784	to	_	_	_	_
25-14	2785-2788	the	abstract[159]	giv[159]	_	_
25-15	2789-2797	visceral	abstract[159]	giv[159]	_	_
25-16	2798-2801	fat	substance|abstract[159]	giv|giv[159]	_	_
25-17	2802-2806	area	abstract[159]	giv[159]	_	_
25-18	2807-2809	on	abstract[159]	giv[159]	_	_
25-19	2810-2814	body	abstract[159]|object|abstract[162]	giv[159]|giv|new[162]	_	_
25-20	2815-2826	composition	abstract[159]|abstract|abstract[162]	giv[159]|giv|new[162]	_	_
25-21	2827-2835	analysis	abstract[159]|abstract[162]	giv[159]|new[162]	_	_
25-22	2836-2837	,	abstract[159]|abstract[162]	giv[159]|new[162]	_	_
25-23	2838-2848	especially	abstract[159]|abstract[162]|abstract[164]	giv[159]|new[162]|new[164]	_	_
25-24	2849-2851	in	abstract[159]|abstract[162]|abstract[164]	giv[159]|new[162]|new[164]	_	_
25-25	2852-2855	the	abstract[159]|abstract[162]|abstract[164]	giv[159]|new[162]|new[164]	_	_
25-26	2856-2864	research	abstract[159]|abstract[162]|abstract|abstract[164]	giv[159]|new[162]|new|new[164]	_	_
25-27	2865-2872	setting	abstract[159]|abstract[162]|abstract[164]	giv[159]|new[162]|new[164]	_	_
25-28	2873-2874	,	_	_	_	_
25-29	2875-2882	because	_	_	_	_
25-30	2883-2886	the	abstract[165]	new[165]	_	_
25-31	2887-2893	impact	abstract[165]	new[165]	_	_
25-32	2894-2896	of	abstract[165]	new[165]	_	_
25-33	2897-2904	obesity	abstract[165]|abstract	new[165]|giv	coref	28-5[178_0]
25-34	2905-2907	on	abstract[165]	new[165]	_	_
25-35	2908-2910	LT	abstract[165]|abstract	new[165]|giv	coref	27-8
25-36	2911-2914	may	_	_	_	_
25-37	2915-2917	be	_	_	_	_
25-38	2918-2926	modified	_	_	_	_
25-39	2927-2929	by	_	_	_	_
25-40	2930-2933	the	abstract[168]	new[168]	_	_
25-41	2934-2945	coexistence	abstract[168]	new[168]	_	_
25-42	2946-2948	of	abstract[168]	new[168]	_	_
25-43	2949-2959	sarcopenia	abstract[168]|abstract	new[168]|giv	_	_
25-44	2960-2961	,	abstract[168]	new[168]	_	_
25-45	2962-2974	myosteatosis	abstract[168]	new[168]	_	_
25-46	2975-2976	,	abstract[168]	new[168]	_	_
25-47	2977-2983	and/or	abstract[168]	new[168]	_	_
25-48	2984-2987	low	abstract[168]|object[172]	new[168]|giv[172]	_	_
25-49	2988-3000	subcutaneous	abstract[168]|abstract|object[172]	new[168]|giv|giv[172]	_	_
25-50	3001-3008	adipose	abstract[168]|abstract|object[172]	new[168]|giv|giv[172]	_	_
25-51	3009-3015	tissue	abstract[168]|object[172]	new[168]|giv[172]	_	_
25-52	3016-3017	.	_	_	_	_

#Text=2.2 .
26-1	3018-3021	2.2	abstract	new	_	_
26-2	3022-3023	.	_	_	_	_

#Text=Should Morbidly Obese Patients be Listed for LT ?
27-1	3024-3030	Should	_	_	_	_
27-2	3031-3039	Morbidly	person[174]	giv[174]	coref	30-4[190_174]
27-3	3040-3045	Obese	person[174]	giv[174]	_	_
27-4	3046-3054	Patients	person[174]	giv[174]	_	_
27-5	3055-3057	be	_	_	_	_
27-6	3058-3064	Listed	_	_	_	_
27-7	3065-3068	for	_	_	_	_
27-8	3069-3071	LT	abstract	giv	coref	28-2
27-9	3072-3073	?	_	_	_	_

#Text=Some LT programs consider morbid obesity a relative contraindication for LT based on the latest recommendations from the American Association for the Study of the Liver .
28-1	3074-3078	Some	abstract[177]	new[177]	_	_
28-2	3079-3081	LT	abstract|abstract[177]	giv|new[177]	coref	28-11
28-3	3082-3090	programs	abstract[177]	new[177]	_	_
28-4	3091-3099	consider	_	_	_	_
28-5	3100-3106	morbid	abstract[178]	giv[178]	coref	29-8[0_178]
28-6	3107-3114	obesity	abstract[178]	giv[178]	_	_
28-7	3115-3116	a	abstract[179]	new[179]	coref	33-35[242_179]
28-8	3117-3125	relative	abstract[179]	new[179]	_	_
28-9	3126-3142	contraindication	abstract[179]	new[179]	_	_
28-10	3143-3146	for	abstract[179]	new[179]	_	_
28-11	3147-3149	LT	abstract[179]|abstract	new[179]|giv	coref	29-12
28-12	3150-3155	based	_	_	_	_
28-13	3156-3158	on	_	_	_	_
28-14	3159-3162	the	abstract[181]	new[181]	_	_
28-15	3163-3169	latest	abstract[181]	new[181]	_	_
28-16	3170-3185	recommendations	abstract[181]	new[181]	_	_
28-17	3186-3190	from	abstract[181]	new[181]	_	_
28-18	3191-3194	the	abstract[181]|organization[182]	new[181]|giv[182]	_	_
28-19	3195-3203	American	abstract[181]|organization[182]	new[181]|giv[182]	_	_
28-20	3204-3215	Association	abstract[181]|organization[182]	new[181]|giv[182]	_	_
28-21	3216-3219	for	abstract[181]|organization[182]	new[181]|giv[182]	_	_
28-22	3220-3223	the	abstract[181]|organization[182]|abstract[183]	new[181]|giv[182]|new[183]	_	_
28-23	3224-3229	Study	abstract[181]|organization[182]|abstract[183]	new[181]|giv[182]|new[183]	_	_
28-24	3230-3232	of	abstract[181]|organization[182]|abstract[183]	new[181]|giv[182]|new[183]	_	_
28-25	3233-3236	the	abstract[181]|organization[182]|abstract[183]|object[184]	new[181]|giv[182]|new[183]|giv[184]	coref	32-26[0_184]
28-26	3237-3242	Liver	abstract[181]|organization[182]|abstract[183]|object[184]	new[181]|giv[182]|new[183]|giv[184]	_	_
28-27	3243-3244	.	_	_	_	_

#Text=However , evidence evaluating the role of obesity on outcomes after LT is conflicting .
29-1	3245-3252	However	abstract[185]	new[185]	coref	31-1[0_185]
29-2	3253-3254	,	abstract[185]	new[185]	_	_
29-3	3255-3263	evidence	abstract[185]	new[185]	_	_
29-4	3264-3274	evaluating	_	_	_	_
29-5	3275-3278	the	abstract[186]	new[186]	_	_
29-6	3279-3283	role	abstract[186]	new[186]	_	_
29-7	3284-3286	of	abstract[186]	new[186]	_	_
29-8	3287-3294	obesity	abstract[186]|abstract	new[186]|giv	coref	30-6[191_0]
29-9	3295-3297	on	_	_	_	_
29-10	3298-3306	outcomes	abstract	giv	coref	32-17[222_0]
29-11	3307-3312	after	_	_	_	_
29-12	3313-3315	LT	abstract	giv	coref	30-13
29-13	3316-3318	is	_	_	_	_
29-14	3319-3330	conflicting	_	_	_	_
29-15	3331-3332	.	_	_	_	_

#Text=When needed , patients with severe and morbid obesity do benefit from LT , meaning they live longer than they would do without it , and LT in these patients strays far away from being futile , with five-year survival rates well above 50 % .
30-1	3333-3337	When	_	_	_	_
30-2	3338-3344	needed	_	_	_	_
30-3	3345-3346	,	_	_	_	_
30-4	3347-3355	patients	person[190]	giv[190]	ana	30-16[0_190]
30-5	3356-3360	with	person[190]	giv[190]	_	_
30-6	3361-3367	severe	person[190]|abstract[191]	giv[190]|giv[191]	coref	31-20[0_191]
30-7	3368-3371	and	person[190]|abstract[191]	giv[190]|giv[191]	_	_
30-8	3372-3378	morbid	person[190]|abstract[191]	giv[190]|giv[191]	_	_
30-9	3379-3386	obesity	person[190]|abstract[191]	giv[190]|giv[191]	_	_
30-10	3387-3389	do	_	_	_	_
30-11	3390-3397	benefit	_	_	_	_
30-12	3398-3402	from	_	_	_	_
30-13	3403-3405	LT	abstract	giv	ana	30-24
30-14	3406-3407	,	_	_	_	_
30-15	3408-3415	meaning	_	_	_	_
30-16	3416-3420	they	person	giv	ana	30-20
30-17	3421-3425	live	_	_	_	_
30-18	3426-3432	longer	_	_	_	_
30-19	3433-3437	than	_	_	_	_
30-20	3438-3442	they	person	giv	coref	30-30
30-21	3443-3448	would	_	_	_	_
30-22	3449-3451	do	_	_	_	_
30-23	3452-3459	without	_	_	_	_
30-24	3460-3462	it	abstract	giv	coref	30-27[196_0]
30-25	3463-3464	,	_	_	_	_
30-26	3465-3468	and	_	_	_	_
30-27	3469-3471	LT	abstract[196]	giv[196]	coref	31-17[0_196]
30-28	3472-3474	in	abstract[196]	giv[196]	_	_
30-29	3475-3480	these	abstract[196]|object[198]	giv[196]|new[198]	_	_
30-30	3481-3489	patients	abstract[196]|person|object[198]	giv[196]|giv|new[198]	_	_
30-31	3490-3496	strays	abstract[196]|object[198]	giv[196]|new[198]	_	_
30-32	3497-3500	far	_	_	_	_
30-33	3501-3505	away	_	_	_	_
30-34	3506-3510	from	_	_	_	_
30-35	3511-3516	being	_	_	_	_
30-36	3517-3523	futile	_	_	_	_
30-37	3524-3525	,	_	_	_	_
30-38	3526-3530	with	_	_	_	_
30-39	3531-3540	five-year	abstract[200]	new[200]	_	_
30-40	3541-3549	survival	event|abstract[200]	new|new[200]	coref	32-33[227_0]
30-41	3550-3555	rates	abstract[200]	new[200]	_	_
30-42	3556-3560	well	abstract[200]|quantity[201]	new[200]|new[201]	_	_
30-43	3561-3566	above	abstract[200]|quantity[201]	new[200]|new[201]	_	_
30-44	3567-3569	50	abstract[200]|quantity[201]	new[200]|new[201]	_	_
30-45	3570-3571	%	abstract[200]|quantity[201]	new[200]|new[201]	_	_
30-46	3572-3573	.	_	_	_	_

#Text=Evidence so far does not support using a strict BMI cutoff to deny someone candidacy for LT , however obesity is frequently associated with other conditions that may be contraindications for LT such as cardiovascular disease , cancer , renal dysfunction , and pulmonary hypertension .
31-1	3574-3582	Evidence	abstract	giv	_	_
31-2	3583-3585	so	_	_	_	_
31-3	3586-3589	far	_	_	_	_
31-4	3590-3594	does	_	_	_	_
31-5	3595-3598	not	_	_	_	_
31-6	3599-3606	support	_	_	_	_
31-7	3607-3612	using	_	_	_	_
31-8	3613-3614	a	abstract[204]	new[204]	_	_
31-9	3615-3621	strict	abstract[204]	new[204]	_	_
31-10	3622-3625	BMI	organization|abstract[204]	giv|new[204]	_	_
31-11	3626-3632	cutoff	abstract[204]	new[204]	_	_
31-12	3633-3635	to	_	_	_	_
31-13	3636-3640	deny	_	_	_	_
31-14	3641-3648	someone	person|abstract[206]	new|new[206]	_	_
31-15	3649-3658	candidacy	abstract[206]	new[206]	_	_
31-16	3659-3662	for	abstract[206]	new[206]	_	_
31-17	3663-3665	LT	abstract[206]|abstract	new[206]|giv	coref	31-32[211_0]
31-18	3666-3667	,	_	_	_	_
31-19	3668-3675	however	_	_	_	_
31-20	3676-3683	obesity	abstract	giv	coref	32-3
31-21	3684-3686	is	_	_	_	_
31-22	3687-3697	frequently	_	_	_	_
31-23	3698-3708	associated	_	_	_	_
31-24	3709-3713	with	_	_	_	_
31-25	3714-3719	other	abstract[209]	new[209]	_	_
31-26	3720-3730	conditions	abstract[209]	new[209]	_	_
31-27	3731-3735	that	_	_	_	_
31-28	3736-3739	may	_	_	_	_
31-29	3740-3742	be	_	_	_	_
31-30	3743-3760	contraindications	abstract[210]	new[210]	_	_
31-31	3761-3764	for	abstract[210]	new[210]	_	_
31-32	3765-3767	LT	abstract[210]|abstract[211]	new[210]|giv[211]	coref	33-22[0_211]
31-33	3768-3772	such	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
31-34	3773-3775	as	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
31-35	3776-3790	cardiovascular	abstract[210]|abstract[211]|abstract[212]	new[210]|giv[211]|new[212]	coref	32-26[226_212]
31-36	3791-3798	disease	abstract[210]|abstract[211]|abstract[212]	new[210]|giv[211]|new[212]	_	_
31-37	3799-3800	,	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
31-38	3801-3807	cancer	abstract[210]|abstract[211]|abstract	new[210]|giv[211]|new	_	_
31-39	3808-3809	,	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
31-40	3810-3815	renal	abstract[210]|abstract[211]|abstract|abstract[215]	new[210]|giv[211]|new|new[215]	_	_
31-41	3816-3827	dysfunction	abstract[210]|abstract[211]|abstract[215]	new[210]|giv[211]|new[215]	_	_
31-42	3828-3829	,	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
31-43	3830-3833	and	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
31-44	3834-3843	pulmonary	abstract[210]|abstract[211]|person|abstract[217]	new[210]|giv[211]|new|new[217]	_	_
31-45	3844-3856	hypertension	abstract[210]|abstract[211]|abstract[217]	new[210]|giv[211]|new[217]	_	_
31-46	3857-3858	.	_	_	_	_

#Text=Also , obesity is a risk factor for NAFLD , which though traditionally considered to have similar post-LT outcomes to those of other etiologies of liver disease , may in fact have lower one-year survival due to cardiovascular and cerebrovascular diseases .
32-1	3859-3863	Also	_	_	_	_
32-2	3864-3865	,	_	_	_	_
32-3	3866-3873	obesity	abstract	giv	coref	32-5[220_0]
32-4	3874-3876	is	_	_	_	_
32-5	3877-3878	a	abstract[220]	giv[220]	coref	33-6[0_220]
32-6	3879-3883	risk	abstract|abstract[220]	new|giv[220]	_	_
32-7	3884-3890	factor	abstract[220]	giv[220]	_	_
32-8	3891-3894	for	abstract[220]	giv[220]	_	_
32-9	3895-3900	NAFLD	abstract[220]|abstract	giv[220]|new	ana	32-21[223_0]
32-10	3901-3902	,	_	_	_	_
32-11	3903-3908	which	_	_	_	_
32-12	3909-3915	though	_	_	_	_
32-13	3916-3929	traditionally	_	_	_	_
32-14	3930-3940	considered	_	_	_	_
32-15	3941-3943	to	_	_	_	_
32-16	3944-3948	have	_	_	_	_
32-17	3949-3956	similar	abstract[222]	giv[222]	coref	33-22[239_222]
32-18	3957-3964	post-LT	abstract[222]	giv[222]	_	_
32-19	3965-3973	outcomes	abstract[222]	giv[222]	_	_
32-20	3974-3976	to	_	_	_	_
32-21	3977-3982	those	abstract[223]	giv[223]	_	_
32-22	3983-3985	of	abstract[223]	giv[223]	_	_
32-23	3986-3991	other	abstract[223]|abstract[224]	giv[223]|new[224]	_	_
32-24	3992-4002	etiologies	abstract[223]|abstract[224]	giv[223]|new[224]	_	_
32-25	4003-4005	of	abstract[223]|abstract[224]	giv[223]|new[224]	_	_
32-26	4006-4011	liver	abstract[223]|abstract[224]|object|abstract[226]	giv[223]|new[224]|giv|giv[226]	_	_
32-27	4012-4019	disease	abstract[223]|abstract[224]|abstract[226]	giv[223]|new[224]|giv[226]	_	_
32-28	4020-4021	,	_	_	_	_
32-29	4022-4025	may	_	_	_	_
32-30	4026-4028	in	_	_	_	_
32-31	4029-4033	fact	_	_	_	_
32-32	4034-4038	have	_	_	_	_
32-33	4039-4044	lower	event[227]	giv[227]	_	_
32-34	4045-4053	one-year	event[227]	giv[227]	_	_
32-35	4054-4062	survival	event[227]	giv[227]	_	_
32-36	4063-4066	due	_	_	_	_
32-37	4067-4069	to	_	_	_	_
32-38	4070-4084	cardiovascular	abstract	new	_	_
32-39	4085-4088	and	_	_	_	_
32-40	4089-4104	cerebrovascular	abstract	new	_	_
32-41	4105-4113	diseases	abstract	new	_	_
32-42	4114-4115	.	_	_	_	_

#Text=In summary , more than obesity itself , it is the sum of the comorbidities of the individual patient that determines LT outcomes and as such , morbid obesity should not be considered on its own a contraindication for LT , but in turn should trigger a rigorous pre-LT assessment to carefully select potential recipients , as discussed below .
33-1	4116-4118	In	_	_	_	_
33-2	4119-4126	summary	abstract	new	ana	33-6[233_0]
33-3	4127-4128	,	_	_	_	_
33-4	4129-4133	more	_	_	_	_
33-5	4134-4138	than	_	_	_	_
33-6	4139-4146	obesity	abstract|abstract[233]	giv|giv[233]	ana|coref|ana|coref	33-9[0_233]|33-28[240_0]|33-9[0_233]|33-28[240_0]
33-7	4147-4153	itself	abstract[233]	giv[233]	_	_
33-8	4154-4155	,	_	_	_	_
33-9	4156-4158	it	quantity	giv	coref	33-11[235_0]
33-10	4159-4161	is	_	_	_	_
33-11	4162-4165	the	quantity[235]	giv[235]	ana	33-35[0_235]
33-12	4166-4169	sum	quantity[235]	giv[235]	_	_
33-13	4170-4172	of	quantity[235]	giv[235]	_	_
33-14	4173-4176	the	quantity[235]|abstract[236]	giv[235]|new[236]	_	_
33-15	4177-4190	comorbidities	quantity[235]|abstract[236]	giv[235]|new[236]	_	_
33-16	4191-4193	of	quantity[235]|abstract[236]	giv[235]|new[236]	_	_
33-17	4194-4197	the	quantity[235]|abstract[236]|person[237]	giv[235]|new[236]|giv[237]	_	_
33-18	4198-4208	individual	quantity[235]|abstract[236]|person[237]	giv[235]|new[236]|giv[237]	_	_
33-19	4209-4216	patient	quantity[235]|abstract[236]|person[237]	giv[235]|new[236]|giv[237]	_	_
33-20	4217-4221	that	_	_	_	_
33-21	4222-4232	determines	_	_	_	_
33-22	4233-4235	LT	abstract|abstract[239]	giv|giv[239]	coref|coref	33-40|33-40
33-23	4236-4244	outcomes	abstract[239]	giv[239]	_	_
33-24	4245-4248	and	_	_	_	_
33-25	4249-4251	as	_	_	_	_
33-26	4252-4256	such	_	_	_	_
33-27	4257-4258	,	_	_	_	_
33-28	4259-4265	morbid	abstract[240]	giv[240]	_	_
33-29	4266-4273	obesity	abstract[240]	giv[240]	_	_
33-30	4274-4280	should	_	_	_	_
33-31	4281-4284	not	_	_	_	_
33-32	4285-4287	be	_	_	_	_
33-33	4288-4298	considered	_	_	_	_
33-34	4299-4301	on	_	_	_	_
33-35	4302-4305	its	abstract|abstract[242]	giv|giv[242]	_	_
33-36	4306-4309	own	abstract[242]	giv[242]	_	_
33-37	4310-4311	a	abstract[242]	giv[242]	_	_
33-38	4312-4328	contraindication	abstract[242]	giv[242]	_	_
33-39	4329-4332	for	abstract[242]	giv[242]	_	_
33-40	4333-4335	LT	abstract[242]|abstract	giv[242]|giv	_	_
33-41	4336-4337	,	_	_	_	_
33-42	4338-4341	but	_	_	_	_
33-43	4342-4344	in	_	_	_	_
33-44	4345-4349	turn	abstract	new	_	_
33-45	4350-4356	should	_	_	_	_
33-46	4357-4364	trigger	_	_	_	_
33-47	4365-4366	a	abstract[245]	new[245]	_	_
33-48	4367-4375	rigorous	abstract[245]	new[245]	_	_
33-49	4376-4382	pre-LT	abstract[245]	new[245]	_	_
33-50	4383-4393	assessment	abstract[245]	new[245]	_	_
33-51	4394-4396	to	_	_	_	_
33-52	4397-4406	carefully	_	_	_	_
33-53	4407-4413	select	_	_	_	_
33-54	4414-4423	potential	person[246]	new[246]	_	_
33-55	4424-4434	recipients	person[246]	new[246]	_	_
33-56	4435-4436	,	_	_	_	_
33-57	4437-4439	as	_	_	_	_
33-58	4440-4449	discussed	_	_	_	_
33-59	4450-4455	below	_	_	_	_
33-60	4456-4457	.	_	_	_	_
